{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T21:28:54Z","timestamp":1774906134780,"version":"3.50.1"},"reference-count":58,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>We investigated whether prolonged treatment with omalizumab influences development or progression of solid epithelial cancer in patients with atopic asthma or chronic idiopathic urticaria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Systematic review and meta\u2010analysis of intervention and observational studies. Randomized controlled trials were assessed for risk of bias using the Cochrane Risk of Bias tool, comparative observational studies were assessed using the Newcastle\u2010Ottawa Scale, and non\u2010comparative observational studies were assessed using the Joanna Briggs Institute Checklist for Prevalence Studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data sources<\/jats:title><jats:p>We searched MEDLINE, EMBASE, Cochrane Library and grey literature for eligible studies to November 2017. All searches were updated in January 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Eligibility criteria for included studies<\/jats:title><jats:p>Randomized, quasi\u2010randomized, controlled clinical trials and observational studies were included if they involved patients \u2265\u00a012\u00a0years with moderate\u2010to\u2010severe persistent asthma or chronic idiopathic urticaria treated with omalizumab for \u2265\u00a040\u00a0weeks. Eligible comparators included standard of care, placebo, cromoglycate or no treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and sixty seven unique studies were eligible for inclusion; however, only twelve (7.2%, n\u00a0=\u00a011 758) reported any outcome of interest, none of which involved patients with urticaria. 195 cancer events were reported. We found no statistically significant increase in the odds of study\u2010emergent solid epithelial cancer in patients randomized to long\u2010term treatment with omalizumab compared to standard of care (Peto OR: 0.65, 95% CI: 0.11, 3.74, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a041%). Less than one per cent of participants of non\u2010comparative observational studies (n\u00a0=\u00a02350) were diagnosed with a solid epithelial tumour (meta\u2010proportion: 0.86% [95% CI: 0.24, 1.86%, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a056%]). In the only comparative observational study reporting on cancer, the proportion of study\u2010emergent solid epithelial tumour events was nearly identical in both study groups (omalizumab: 2.3%, standard of care: 2.2%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There is insufficient evidence to determine whether long\u2010term treatment with omalizumab influences development or progression of solid epithelial cancer in these patient populations.<\/jats:p><jats:p>PROSPERO registration\u00a0# CRD\u00a042018082211.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cea.13457","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T18:19:53Z","timestamp":1562869193000},"page":"1291-1305","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Influence of prolonged treatment with omalizumab on the development of solid epithelial cancer in patients with atopic asthma and chronic idiopathic urticaria: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1934-7867","authenticated-orcid":false,"given":"Amy","family":"Johnston","sequence":"first","affiliation":[{"name":"Cardiovascular Research Methods Centre University of Ottawa Heart Institute Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Smith","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Centre University of Ottawa Heart Institute Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine","family":"Zheng","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Centre University of Ottawa Heart Institute Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn D.","family":"Aaron","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine The Ottawa Hospital Ottawa ON Canada"},{"name":"Ottawa Hospital Research Institute Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon E.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Centre University of Ottawa Heart Institute Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becky","family":"Skidmore","sequence":"additional","affiliation":[{"name":"Independent Information Specialist Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Wells","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Methods Centre University of Ottawa Heart Institute Ottawa ON Canada"},{"name":"School of Epidemiology and Public Health University of Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-2113.63609"},{"key":"e_1_2_8_3_1","first-page":"12","article-title":"IgE\u2010Related Chronic Diseases and Anti\u2010IgE\u2010Based Treatments","volume":"2016","author":"Navins\u2010Ferrer A","year":"2016","journal-title":"J Immunol Res"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.05.015"},{"key":"e_1_2_8_5_1","first-page":"45\u2010460","volume-title":"Review of Medical Microbiology and Immunology","author":"Levinson W","year":"2006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-015-0067-z"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2011.1.1.12"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000284"},{"key":"e_1_2_8_9_1","volume-title":"Xolair (omalizumab) [product monograph]. Dorval","author":"Inc N","year":"2015"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/72601"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.3.2.371"},{"issue":"2","key":"e_1_2_8_12_1","first-page":"117","article-title":"Treating atopic asthma with the anti\u2010IgE monoclonal antibody","volume":"57","author":"D'Amato G","year":"2002","journal-title":". Monaldi archives for chest disease =. Archivio Monaldi per le malattie del torace"},{"key":"e_1_2_8_13_1","first-page":"329","volume-title":"New and Exploratory Therapeutic Agents for Asthma: Lung Biology in Health and Disease","author":"Fahy J","year":"2000"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.11.053"},{"key":"e_1_2_8_15_1","unstructured":"Global Initiative for Asthma.Global Strategy for Asthma Management and Prevention.2017.www.ginasthma.org. Accessed November 6 2017."},{"key":"e_1_2_8_16_1","unstructured":"National Asthma Education and Prevention Program \u2010 Third Expert Panel on the Diagnosis and Management of Asthma.Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda MD: National Heart Lung and Blood Institute (US);2007.www.ncbi.nlm.nih.gov\/books\/NBK7232\/. Accessed December 2 2017."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12494"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8628-1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622317690494"},{"key":"e_1_2_8_20_1","unstructured":"CanadaH.Notice of Compliance (Omalizumab).2014.https:\/\/health-products.canada.ca\/noc-ac\/info.do?xml:lang=en&no=15992. Accessed November 15 2017."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01768.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.02.020"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.02.007"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.09.017"},{"issue":"4","key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7555\/JBR.30.20150038","article-title":"Roles and relevance of mast cells in infection and vaccination","volume":"30","author":"Fang Y","year":"2016","journal-title":"Journal of Biomedical Research"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"e_1_2_8_27_1","unstructured":"BalkEM ChungM ChenML TrikalinosTA LKWC.Assessing the Accuracy of Google Translate to Allow Data Extraction From Trials Published in Non\u2010English Languages. Methods Research Report. (Prepared by the Tufts Evidence\u2010based Practice Center under Contract No. 290\u20132007\u201010055\u20101.). Rockville MD: Agency for Healthcare Research and Quality; 2013.www.effectivehealthcare.ahrq.gov\/reports\/final.cfm. Accessed November 8 2017."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_8_29_1","unstructured":"WellsG SheaB O'connellD et al.The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses. Ottawa (ON): Ottawa Hospital Research Institute; 2009. Available in March.2016."},{"key":"e_1_2_8_30_1","unstructured":"Checklist for Prevalence Studies. Australia: The Joanna Briggs Institute.2017."},{"key":"e_1_2_8_31_1","volume-title":"Chapter 9: Analysing data and undertaking meta\u2010analyses","author":"Deeks J","year":"2008"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010983"},{"key":"e_1_2_8_33_1","volume-title":"Chapter 16: Special Topics in Statistics","author":"Higgins J","year":"2008"},{"issue":"11","key":"e_1_2_8_34_1","first-page":"974","article-title":"Meta\u2010analysis of prevalence. Journal of Epidemiology and Community","volume":"67","author":"Barendregt JJ","year":"2013","journal-title":"Health"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/2331205X.2017.1334318"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3258-72-39"},{"key":"e_1_2_8_37_1","volume-title":"editors. Chapter 10: Addressing reporting biases. West Sussex: Wiley\u2010Blackwell","author":"Sterne J","year":"2008"},{"key":"e_1_2_8_38_1","first-page":"1141","article-title":"The eXpeRience registry: the 'real\u2010world' effectiveness of omalizumab in allergic asthma","volume":"107","author":"Braunstahl GJ","year":"2013","journal-title":"RespirMed"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.09.056"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-014-0034-7"},{"key":"e_1_2_8_41_1","first-page":"36","article-title":"Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety","volume":"124","author":"Mansur AH","year":"2017","journal-title":"RespirMed"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.09.006"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2012.07.006"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00278102"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-9-201105030-00002"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.054"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.394"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1159\/000488349"},{"key":"e_1_2_8_49_1","unstructured":"HowardJ.Minimum Latency & Types or Categories of Cancer. Centers for Disease Control and Prevention\u2010 World Trade Centre Health Program.2014."},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03214.x"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.01.033"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy236"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90164-3"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.017"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2017.01.009"},{"key":"e_1_2_8_56_1","unstructured":"Department of Health Information and Research.Malta National Cancer Registry: Female Breast Cancer.2014.https:\/\/deputyprimeminister.gov.mt\/\/en\/dhir\/documents\/cancer\/2014\/breast%202014.pdf"},{"key":"e_1_2_8_57_1","unstructured":"HigginsJ GreenS eds.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration.2011. Accessed April 2 2019."},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.08.010"},{"issue":"1","key":"e_1_2_8_59_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/1055-9965.20.14.1","article-title":"Epidemiology of male breast cancer","volume":"14","author":"Weiss JR","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcea.13457","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13457","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cea.13457","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T21:02:23Z","timestamp":1694206943000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.13457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/cea.13457"],"URL":"https:\/\/doi.org\/10.1111\/cea.13457","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"assertion":[{"value":"2018-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}